Epigallocatechin gallate nanocarriers: from physicochemical design to claim-specific evidence and translational requirements

Epigallocatechin gallate (EGCG) is a polyphenolic flavan-3-ol with broad experimental bioactivity, but oral translation is constrained by chemical lability, restricted intestinal transport, active efflux, extensive presystemic metabolism, and highly variable systemic exposure. Nanocarriers can protect EGCG, modify release, enhance local transport, or increase exposure in selected formulations; however, these effects cannot be inferred from particle size, polydispersity index (PDI), zeta potential, or encapsulation efficiency (EE) alone and cannot be generalized across carrier classes. Recent reviews already synthesize EGCG nanocarrier formulations, biological effects, pharmacokinetic observations, safety considerations, and translational challenges. This critical narrative review addresses a complementary question: what formulation-specific evidence is sufficient to support claims of protection, permeability enhancement, pharmacokinetic improvement, efficacy, or human translation? We link intrinsic EGCG chemistry to carrier selection and appraise a defined 31-study formulation-level set by route, dose context, analyte, comparator/control, endpoint, and directly supported magnitude while separating direct from surrogate evidence. An author-developed six-level conceptual hierarchy maps directly measured endpoints from physicochemical characterization to human outcomes, alongside separate appraisal of comparators, controls, analyte specificity, and internal-validity limitations. Its numbering is a heuristic of broad proximity to clinical inference, not a validated study-quality score or a mandatory sequence across routes. Across carrier classes, performance is formulation- and endpoint-specific; translation requires appropriate EGCG-dose-matched comparators, route-appropriate systemic pharmacokinetics or local-delivery evidence, formulation-specific safety, and efficacy rather than favorable particle metrics alone.

Authors

Institutions

Publication Details

Journal
Frontiers in Nanotechnology
Published
2026-11-16
DOI
https://doi.org/10.3389/fnano.2026.1984510
Primary Topic
Tea Polyphenols and Effects
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epigallocatechin gallate nanocarriers: from physicochemical design to claim-specific evidence and translational requirements

Gabriela Valenzuela-Barra, León Goïty, Paula Jorquera, Iván D. Mesías-Muñoz et al.
Frontiers in Nanotechnology
Tea Polyphenols and Effects
article

Epigallocatechin gallate nanocarriers: from physicochemical design to claim-specific evidence and translational requirements

Gabriela Valenzuela-Barra, León Goïty, Paula Jorquera, Iván D. Mesías-Muñoz, Javier O. Morales
article en

Abstract

Epigallocatechin gallate (EGCG) is a polyphenolic flavan-3-ol with broad experimental bioactivity, but oral translation is constrained by chemical lability, restricted intestinal transport, active efflux, extensive presystemic metabolism, and highly variable systemic exposure. Nanocarriers can protect EGCG, modify release, enhance local transport, or increase exposure in selected formulations; however, these effects cannot be inferred from particle size, polydispersity index (PDI), zeta potential, or encapsulation efficiency (EE) alone and cannot be generalized across carrier classes. Recent reviews already synthesize EGCG nanocarrier formulations, biological effects, pharmacokinetic observations, safety considerations, and translational challenges. This critical narrative review addresses a complementary question: what formulation-specific evidence is sufficient to support claims of protection, permeability enhancement, pharmacokinetic improvement, efficacy, or human translation? We link intrinsic EGCG chemistry to carrier selection and appraise a defined 31-study formulation-level set by route, dose context, analyte, comparator/control, endpoint, and directly supported magnitude while separating direct from surrogate evidence. An author-developed six-level conceptual hierarchy maps directly measured endpoints from physicochemical characterization to human outcomes, alongside separate appraisal of comparators, controls, analyte specificity, and internal-validity limitations. Its numbering is a heuristic of broad proximity to clinical inference, not a validated study-quality score or a mandatory sequence across routes. Across carrier classes, performance is formulation- and endpoint-specific; translation requires appropriate EGCG-dose-matched comparators, route-appropriate systemic pharmacokinetics or local-delivery evidence, formulation-specific safety, and efficacy rather than favorable particle metrics alone.

Frontiers in NanotechnologyVol. 8
Universidad de Antofagasta (CL), Center of New Drugs for Hypertension (CL), Advanced Center for Chronic Diseases (CL), University of Chile (CL)
Agencia Nacional de Investigación y Desarrollo, Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias
Good health and well-being
Tea Polyphenols and Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon